Aspen Neuroscience IPO: offering terms from its S-1
Aspen Neuroscience filed its S-1 on 9 Oct 2026 to list on Nasdaq as ASPE, and has amended it 2 times. It set a price range of $15-$17 a share.
Headlines
- Net loss, 2025
- $62M
- Price range
- $15-$17
- $150M at the midpoint
Aspen Neuroscience IPO terms
From the newest registration statement. Terms left blank there are not set yet.
- Exchange
- Nasdaq Global Select Market
- Ticker
- ASPE
- Price range
- $15-$17
- Shares offered
- 9,375,000
- Expected to raise
- $150M at the midpoint
- Registered
- $183M, the amount the filing fee is paid on
- Underwriters
- Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel and Oppenheimer & Co.
- First filed
- 9 Oct 2026
Aspen Neuroscience revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$59M | -$62M |
| First half of 2026 | - | -$38M | -$37M |
Aspen Neuroscience share structure and company facts
- Employees
- 123
- Headquarters
- San Diego, CA
Aspen Neuroscience's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Aspen Neuroscience's newest prospectus (S-1/A filed 26 Oct 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.